本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Crescent Biopharma Inc

19.93
+0.52002.68%
成交量:2.64萬
成交額:52.72萬
市值:7.40億
市盈率:-2.69
高:20.37
開:19.50
低:19.42
收:19.41
52周最高:27.41
52周最低:8.72
股本:3,714.39萬
流通股本:1,595.35萬
量比:0.48
換手率:0.17%
股息:- -
股息率:- -
每股收益(TTM):-7.4105
每股收益(LYR):-12.8150
淨資產收益率:-160.75%
總資產收益率:-69.15%
市淨率:10.20
市盈率(LYR):-1.56

資料載入中...

2022/08/01

重要事件披露

8-K - Current report
2022/08/01

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/07/22

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/07/11

重要事件披露

8-K - Current report
2022/07/01

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/06/27

重要事件披露

8-K - Current report
2022/06/21

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2022/06/17

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/06/09

重要事件披露

8-K - Current report
2022/05/25

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/05/24

重要事件披露

8-K/A [Amend] - Current report
2022/05/23

重要事件披露

8-K - Current report
2022/05/10

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/05/09

重要事件披露

8-K - Current report
2022/05/09

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/05/02

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/05/02

[修訂]年度報告

10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405]
2022/04/21

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/04/05

重要事件披露

8-K - Current report
2022/03/31

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]